Phanes Therapeutics announces first patient dosed in clinical study of peluntamig in combination with atezolizumab

SAN DIEGO, May 5, 2025 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the first patient has been dosed in the clinical study of peluntamig in combination with...